Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

170.68
Delayed Data
As of 3:59pm ET
 +3.01 / +1.80%
Today’s Change
130.09
Today|||52-Week Range
181.81
+5.14%
Year-to-Date
Facebook (FB) Owns Q2 Earnings on Huge Beat, Plus GRPN, GPRO and More
6:28pm / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
4:03pm / Zacks.com - Paid Partner Content
Dr. Michael Burry of 'The Big Short' Portfolio Review Shows Several Large Gains
5:50pm / GuruFocus News - Paid Partner Content
3 Drugs Stocks Pushing Industry Growth
1:18pm / TheStreet.com - Paid Partner Content
Dr. Michael Burry 2016 Portfolio Review Shows Several Large Gains
5:40pm / GuruFocus News - Paid Partner Content
Daniel Loeb's Third Point 2nd-Quarter 2016 Investor Letter
11:30am / GuruFocus News - Paid Partner Content
Market Ends Weak as Rate Hike Put Off: See You in September?
5:01pm / TheStreet.com - Paid Partner Content
Amgen Still Has Many Ways to Win
8:11am / TheStreet.com - Paid Partner Content
Amgen (AMGN) Stock Down in After-Hours Trading Despite Q2 Earnings Beat, Positive Gui...
4:28pm / TheStreet.com - Paid Partner Content
Amgen Inc: What to Watch in Q2 Earnings
Jul 26 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close167.67
Today’s open167.45
Day’s range167.44 - 171.09
Volume4,200,156
Average volume (3 months)2,886,291
Market cap$126.0B
Dividend yield2.34%
Data as of 3:59pm ET, 07/27/2016

Growth & Valuation

Earnings growth (last year)+35.22%
Earnings growth (this year)+7.78%
Earnings growth (next 5 years)+9.00%
Revenue growth (last year)+6.49%
P/E ratio18.1
Price/Sales5.83
Price/Book4.50

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences+0.74+0.91%
BIIBBiogen+1.31+0.46%
BAXBaxter International...+0.31+0.65%
NBIXNeurocrine Bioscienc...+1.20+2.42%
Data as of 4:00pm ET, 07/27/2016

Financials

Last reporting dateJuly 27, 2016
EPS forecast (this quarter)$2.73
Annual revenue (last year)$21.3B
Annual profit (last year)$6.9B
Net profit margin32.52%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Robert A. Bradway
Executive Vice President-
Operations
Esteban Santos
Corporate headquarters
Thousand Oaks, California

Forecasts

Partner Offers

Search for Jobs